Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCADE: Soticlestat in 15Q Duplication Syndrome or CDKL5 Deficiency Disorder
NCT03694275Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of soticlestat in dup15q syndrome and CDKL5 deficiency disorder (CDD) (2 arms), sponsored by Takeda. Primary endpoint: Percent Change From Baseline in Motor Seizure Frequency Per 28 Days. Started Sep 2018; status: completed.
02
Drugs
soticlestat
03
Conditions
dup15q syndromeCDKL5 deficiency disorder (CDD)
Beyond the preview
Go deeper on NCT03694275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03694275.